1 citations
,
January 2026 in “JAMA Network Open” This study found significant racial and ethnic disparities in the incidence and psychological impact of chemotherapy-related alopecia, with Asian women experiencing the greatest burden, highlighting the need for personalized and culturally sensitive care.
43 citations
,
March 2019 in “JAMA Dermatology” This study found that persistent chemotherapy-induced alopecia is often more severe and diffuse than alopecia from endocrine therapy, with both conditions negatively impacting patients' emotional wellbeing, and moderate to significant improvement was observed with dermatologic therapy.
3 citations
,
July 2018 in “Cureus” This case study reports that a woman with breast cancer experienced persistent alopecia after taxane chemotherapy and endocrine therapy, and significant improvement was seen with topical minoxidil.
July 2026 in “Preprints.org” In this observational study, researchers found that new users of tirzepatide experienced a higher incidence of alopecia compared to semaglutide users over a 12-month period, with increased risk persisting even when accounting for achieved weight loss and treatment duration.
November 2025 in “npj Breast Cancer” In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.